STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds

The FDA has been criticized for including patient and consumer representatives on its advisory panels who have ties to advocacy groups funded by pharmaceutical companies. A STAT+ analysis found that nearly 40% of FDA advisory committee meetings over a 20-year period included such representatives.